A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and ...

Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before ...

ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ...

Glioblastoma remains one of the most feared diagnoses in medicine, and one of its standard treatments has long carried a ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...

The combination of atezolizumab plus bevacizumab could become a standard first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation ...

A Prescription Drug User Fee Act target date of July 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License ...

Combining bevacizumab (Avastin) with standard chemotherapy eases symptoms in patients with platinum-resistant recurrent ovarian cancer, new results from the AURELIA trial confirm. The study ...

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022. The FDA has ...

Tumor angiogenesis, an important step in breast cancer development, invasion, progression, and metastasis, is regulated by the expression of proangiogenic factors such as vascular endothelial growth ...